Alnylam Pharmaceuticals Inc at Cantor Fitzgerald Global Healthcare Conference (Virtual) Transcript
Hey, everybody, it's Alethia Young at Cantor here. I cover large cap, small mid-cap biotech. I'm very happy to have Alnylam Pharmaceuticals. I have Dr. Yvonne Greenstreet. She's the President and COO of the company.
Yvonne, maybe in the first 30 to 60 second, just give us kind of -- it's been, again, another exciting year for Alnylam. Just talk about some of the accomplishments over the past 12 months.
Yes. Alethia, thanks for having me, and it's a real pleasure to be here. Look, this has been an amazing year for us as we continue to progress against our P5x25 strategy. And we're making really good progress on all fronts. And I'm sure we'll cover off many of the achievements as we go through this conversation. But bottom line has been a terrific year for us so far.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
